Q4 2025 · 13F-HR
Redmile Group, LLCholdings as filed
Filed 2026-02-17 · accession 0001104659-26-016433
$1.36B
Reported value
34
Positions
2025-12-31
Period end
The Brief · Redmile Group, LLC · Q4 2025
AI · grounded in 13F
Redmile Group, LLC exited its position in AKRO, reducing its exposure by $35.5M. The fund also closed positions in ETNBGBP for $21.7M and KROS for $8.7M. On the buy side, the fund increased its holdings in NRIX by 120% and ANNX by 59.5%. Redmile Group, LLC ended the period with 34 positions and total AUM of $1.36B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $230.0M | 16.9% | 5,220,846 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $167.1M | 12.3% | 677,705 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $153.5M | 11.3% | 8,093,908 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $128.0M | 9.43% | 4,034,070 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $122.8M | 9.05% | 5,718,385 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $62.9M | 4.63% | 4,368,804 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $55.3M | 4.07% | 15,666,731 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $51.1M | 3.76% | 1,437,918 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $50.5M | 3.72% | 10,050,644 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $35.6M | 2.62% | 1,285,859 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $30.1M | 2.21% | 1,459,599 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $30.0M | 2.21% | 885,927 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $28.8M | 2.12% | 8,253,316 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $28.3M | 2.09% | 3,163,256 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $25.7M | 1.89% | 742,017 | Common | SOLE |
| 82024L103 | STTK | SHATTUCK LABS INC | $20.2M | 1.49% | 5,539,724 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $13.2M | 0.97% | 2,164,777 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $12.9M | 0.95% | 491,654 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $12.6M | 0.93% | 12,872,946 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $10.7M | 0.79% | 1,099,756 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $10.5M | 0.78% | 549,840 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $10.5M | 0.77% | 1,860,542 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC | $9.5M | 0.70% | 435,239 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $8.2M | 0.60% | 112,664 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $8.0M | 0.59% | 441,701 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $7.7M | 0.57% | 283,308 | Common | SOLE |
| G5509L101 | LIVN | LIVANOVA PLC | $7.3M | 0.53% | 118,054 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $6.6M | 0.49% | 2,681,159 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $6.0M | 0.44% | 133,882 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $4.1M | 0.30% | 1,586,174 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $3.7M | 0.27% | 3,264,718 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $3.7M | 0.27% | 448,110 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $2.0M | 0.15% | 1,616,228 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $700,140 | 0.05% | 82,955 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.